Otsuka Pharmaceutical Co., Ltd. (Otsuka Pharmaceutical, Head Office: Tokyo, Japan, President and Representative Director: Taro Iwamoto) and UCB Japan Co. Ltd. (UCB Japan, Head Office: Tokyo, Japan, President and Representative Director: Emmanuel Caeymaex) (solely "UCB" refers to the whole UCB group) today announced the launch of the antiepileptic drug 'E Keppra^®' (nonproprietary name: levetiracetam) 250mg and 500mg tablets, which have completely different mechanism of action from those of conventional medications, on September 17.